Recently, a few studies have reported that the ginsenosides Rh2 and Rg3 could inhibit CSC properties in skin squamous cell carcinoma and breast cancer through reducing the number of Lgr5-positive cells or regulating self-renewal activity, respectively [51,52]. Here, LGR5 is linked to skin squamous cell carcinoma.